1 – 10 of 27
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Dose-volume relationships of planned versus estimated delivered radiation doses to pelvic organs at risk and side effects in patients treated with salvage radiotherapy for recurrent prostate cancer
(
- Contribution to journal › Article
-
Mark
Morbiditet från urinvägar och tarm enligt registerdata efter ultrahypofraktionerad strålbehandling för lokaliserad prostatacancer vid 10 år i HYPO-RT-PC-studien
2024) Onkologidagarna 2024(
- Contribution to conference › Poster
-
Mark
Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
(
- Contribution to conference › Abstract
-
Mark
Register data on long-term morbidity after prostate cancer radiotherapy with ultra-hypofractionated (2.5 weeks) vs conventional (8 weeks) treatment schedules
2024) U21 Health Sciences Group 2024 Doctoral Student Forum(
- Contribution to conference › Poster
-
Mark
Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume : A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule
(
- Contribution to journal › Article
- 2023
-
Mark
MRI-only radiotherapy from an economic perspective : Can new techniques in prostate cancer treatment be cost saving?
(
- Contribution to journal › Article
-
Mark
Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists
(
- Contribution to journal › Article
- 2022
-
Mark
A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial
(
- Contribution to journal › Article
- 2021
-
Mark
Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer
(
- Contribution to journal › Article
-
Mark
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
(
- Contribution to journal › Article